SPECIALTY TOPICS · RESEARCH
Psychedelic Clinical Trials and Mental Health Research: Findings and Limits
Content last updated . This page has not been medically reviewed.
Back to Psychedelic TherapyHow psychedelics act in the brain (neuroscience)
[1] Research on why this might help mood is ongoing; findings from brain imaging or animals are preclinical or biomarker evidence and do not by themselves show a treatment works. See history and neuroscience.Psilocybin and depression: what trials found
Goodwin 2022 [2]
The 25 mg group improved more than the 1 mg control at week 3; the 10 mg group did not. Adverse events in 77% of participants, and suicidal thoughts or self-injury in all dose groups.
Raison 2023 [3]
Larger drop in depression scores than placebo at day 43; more adverse events, including more severe ones, but no serious treatment-related events.
Carhart-Harris 2021 [4]
No significant difference on the main measure at 6 weeks; many secondary outcomes favored psilocybin but were not corrected for multiple comparisons.
Davis 2021 [5]
Used a waiting list instead of a placebo, so participants knew whether they had been treated.
Label: promising but limited. These studies were small to mid-sized, one was funded by a drug company [2], and participants were selected. Trial amounts are study amounts, not recommendations.
Participants in modern studies are screened: NIDA notes people with diagnosed psychosis or bipolar disorder, and sometimes other mental illnesses, are excluded as a precaution. [1] The JAMA trial also excluded active substance use disorder and active suicidal ideation with intent. [3]
Psychedelic-assisted therapy in serious illness
A 2024 Cochrane review of six randomized trials (149 participants with life-threatening illness) found classic psychedelics may reduce anxiety, but judged certainty low to very low because of high risk of bias and small samples. It reported no treatment-related serious adverse events. [6]Where this leaves readers
Research is real and promising for specific groups, in clinics, with screening. It does not support self-treatment. For safety see adverse effects and contraindications and drug interactions and toxicology. For depression or trauma, talk with a clinician: talking with a health professional. In the US, the 988 Suicide & Crisis Lifeline is available by call or text to 988.Frequently asked questions
Is psilocybin therapy FDA approved?
We found no approved psilocybin product in the FDA documents read, only trial guidance and a Breakthrough Therapy designation. Check the FDA for updates. [9][1]
Did psilocybin beat an antidepressant in trials?
In one 59-person trial it did not significantly beat escitalopram on the main measure. [4]
Why do trials say "functional unblinding"?
Because participants can usually tell whether they got a psychedelic, which can inflate results through expectation. [9]
Can these studies be applied to home use?
No. Trials used screened participants, supervision and controlled products, and outcomes outside clinics can differ. [1]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Research limitations (blinding and expectancy)
- Blinding. Participants usually know when they received a drug with strong effects. This is called functional unblinding. The FDA says it can lead to expectation bias in people who feel perceptual effects, and that therapists and raters may also guess. [9] The Cochrane review notes that blinding could not be achieved in all six studies. [6]
- Expectancy. If people hope a treatment will work, they may report improvement. The FDA suggests measuring expectations, checking whether blinding held, and using central raters who do not know the treatment given. [9]
- Therapy versus drug. The FDA states that the contribution of psychotherapy to the overall effect is not established. [9]
- Selection and setting. Screened participants, trained staff and monitored sessions do not match how people use these substances outside trials. NIDA notes poor mental health outcomes may be more likely outside clinical use. [1]
- Durability and safety. The FDA says long-term, blinded follow-up and good tracking of all adverse events, including euphoria-related ones, are needed. [9][8]
Regulatory status
- Other countries: see legal status by country.
References
- National Institute on Drug Abuse. Psychedelic and Dissociative Drugs. Read 2026-10-22.
- Goodwin GM et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 2022. Read 2026-10-22.
- Raison CL et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 2023. Read 2026-10-22.
- Carhart-Harris R et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021. Read 2026-10-22.
- Davis AK et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2021. Read 2026-10-22.
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. Cochrane Database Syst Rev 2024. Read 2026-10-22.
- U.S. Food and Drug Administration. Complete response letter, NDA 215455 (midomafetamine). August 8, 2024. Read 2026-10-22.
- U.S. Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations, guidance for industry. July 2026. Read 2026-10-22.